CoChat
Sign Up
Cited by 77

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimer's disease

Do, Tuan Minh, Alata, Wael, Dodacki, Agnès, Traversy, Marie-Thérèse, Chacun, Hélène, Pradier, Laurent, Scherrmann, Jean-Michel, Farinotti, Robert, Calon, Frédéric, Bourasset, Fanchon·2014·Neuropharmacology
DOI 10.1016/j.neuropharm.2014.02.010
Open this paper in CoChat — free account

Abstract

We evaluated the integrity and function of the blood-brain barrier in 3xTg-AD mice aged 3-18 months and in APP/PS1 mice aged 8-months to determine the impacts of changes in amyloid and tau proteins on the brain vascular changes. The vascular volume (Vvasc) was sub-normal in 3xTg-AD mice aged from 6 to 18 months, but not in the APP/PS1 mice. The uptakes of [(3)H]-diazepam by the brains of 3xTg-AD, APP/PS1 and their age-matched control mice were similar at all the times studied, suggesting that the simple diffusion of small solutes is unchanged in transgenic animals. The uptake of d-glucose by the brains of 18-month old 3xTg-AD mice, but not by those of 8-month old APP/PS1 mice, was reduced compared to their age-matched controls. Accordingly, the amount of Glut-1 protein was 1.4 times lower in the brain capillaries of 18 month-old 3xTg-AD mice than in those of age-matched control mice. We conclude that the brain vascular volume is reduced early in 3xTg-AD mice, 6 months before the appearance of pathological lesions, and that this reduction persists until they are at least 18 months old. The absence of alterations in the BBB of APP/PS1 mice suggests that hyperphosphorylated tau proteins contribute to the vascular changes that occur in AD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2014.02.010

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. Alata, 2014, Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion, Mol. Pharm., 11, 243, 10.1021/mp400421a · DOI
  2. Bell, 2009, Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer's disease, Acta Neuropathol., 118, 103, 10.1007/s00401-009-0522-3 · DOI
  3. Bourasset, 2009, Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease, Neuropharmacology, 56, 808, 10.1016/j.neuropharm.2009.01.006 · DOI · Paper page
  4. Bowman, 2007, Blood–brain barrier impairment in Alzheimer disease: stability and functional significance, Neurology, 68, 1809, 10.1212/01.wnl.0000262031.18018.1a · DOI
  5. Breteler, 2000, Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study, Ann. N. Y. Acad. Sci., 903, 457, 10.1111/j.1749-6632.2000.tb06399.x · DOI
  6. Bronge, 2002, Magnetic resonance imaging in dementia. A study of brain white matter changes, Acta Radiol. Suppl., 1, 10.1034/j.1600-0455.43.s.428.1.x · DOI
  7. Cantin, 2011, Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI, Neuroimage, 58, 579, 10.1016/j.neuroimage.2011.06.070 · DOI
  8. Carnevale, 2012, Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature, Hypertension, 60, 188, 10.1161/HYPERTENSIONAHA.112.195511 · DOI · Paper page
  9. Choeiri, 2002, Immunohistochemical localization and quantification of glucose transporters in the mouse brain, Neuroscience, 111, 19, 10.1016/S0306-4522(01)00619-4 · DOI
  10. Dagenais, 2000, Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice, J. Cereb. Blood Flow Metab., 20, 381, 10.1097/00004647-200002000-00020 · DOI
  11. de la Torre, 2004, Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics, Lancet Neurol., 3, 184, 10.1016/S1474-4422(04)00683-0 · DOI · Paper page
  12. Ding, 2013, Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention, PLoS One, 8, e79977, 10.1371/journal.pone.0079977 · DOI · Paper page
  13. Do, 2013, Oatp1a4 and a L-thyroxine-sensitive transporter mediate the mouse blood–brain barrier transport of amyloid-beta peptide, J. Alzheimers Dis., 36, 555, 10.3233/JAD-121891 · DOI
  14. Do, 2012, ABCG2 and ABCG4-mediated efflux of amyloid-beta peptide 1-40 at the mouse blood-brain barrier, J. Alzheimers Dis., 30, 155, 10.3233/JAD-2012-112189 · DOI
  15. Dorr, 2012, Amyloid-beta-dependent compromise of microvascular structure and function in a model of Alzheimer's disease, Brain, 135, 3039, 10.1093/brain/aws243 · DOI
  16. El Tayara Nel, 2010, Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer's disease, MAGMA, 23, 53, 10.1007/s10334-009-0194-y · DOI
  17. Glodzik, 2011, Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia, J. Cereb. Blood Flow Metab., 31, 671, 10.1038/jcbfm.2010.145 · DOI
  18. Gong, 2006, Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation, J. Alzheimers Dis., 9, 1, 10.3233/JAD-2006-9101 · DOI
  19. Gosselet, 2011, Role of the blood-brain barrier in Alzheimer's disease, Med. Sci. (Paris), 27, 987, 10.1051/medsci/20112711015 · DOI
  20. Hawkins, 2008, Pathophysiology of the blood–brain barrier: animal models and methods, Curr. Top. Dev. Biol., 80, 277, 10.1016/S0070-2153(07)80007-X · DOI
  21. Head, 2010, Loss of caveolin-1 accelerates neurodegeneration and aging, PLoS One, 5, e15697, 10.1371/journal.pone.0015697 · DOI
  22. Hooijmans, 2007, Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice, Brain Res., 1181, 93, 10.1016/j.brainres.2007.08.063 · DOI
  23. Hoyer, 2004, Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications, Adv. Exp. Med. Biol., 541, 135, 10.1007/978-1-4419-8969-7_8 · DOI
  24. Hunter, 2012, Morphological and pathological evolution of the brain microcirculation in aging and Alzheimer's disease, PLoS One, 7, e36893, 10.1371/journal.pone.0036893 · DOI
  25. Jaworski, 2011, Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration, Am. J. Pathol., 179, 2001, 10.1016/j.ajpath.2011.06.025 · DOI
  26. Julien, 2010, High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model, Neurobiol. Aging, 31, 1516, 10.1016/j.neurobiolaging.2008.08.022 · DOI · Paper page
  27. Kalaria, 2002, Small vessel disease and Alzheimer's dementia: pathological considerations, Cerebrovasc. Dis., 13, 48, 10.1159/000049150 · DOI
  28. Kalaria, 1989, Reduced glucose transporter at the blood–brain barrier and in cerebral cortex in Alzheimer disease, J. Neurochem., 53, 1083, 10.1111/j.1471-4159.1989.tb07399.x · DOI · Paper page
  29. Kitaguchi, 2007, Capillary beds are decreased in Alzheimer's disease, but not in Binswanger's disease, Neurosci. Lett., 417, 128, 10.1016/j.neulet.2007.02.021 · DOI
  30. Kovac, 2009, Human truncated tau is using a different mechanism from amyloid-beta to damage the blood-brain barrier, J. Alzheimers Dis., 18, 897, 10.3233/JAD-2009-1197 · DOI
  31. Lee, 2005, Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease, Brain Res. Bull., 65, 317, 10.1016/j.brainresbull.2004.11.024 · DOI
  32. Liu, 2008, Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease, FEBS Lett., 582, 359, 10.1016/j.febslet.2007.12.035 · DOI
  33. Luo, 2010, Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease, Neurobiol. Aging, 33, 933, 10.1016/j.neurobiolaging.2010.08.005 · DOI
  34. Merlini, 2011, Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice, Acta Neuropathol., 122, 293, 10.1007/s00401-011-0834-y · DOI · Paper page
  35. Nagababu, 2009, Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins, J. Alzheimers Dis., 17, 845, 10.3233/JAD-2009-1104 · DOI
  36. Nicolakakis, 2011, Intact memory in TGF-beta1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone, J. Cereb. Blood Flow Metab., 31, 200, 10.1038/jcbfm.2010.78 · DOI
  37. Oddo, 2003, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron, 39, 409, 10.1016/S0896-6273(03)00434-3 · DOI · Paper page
  38. Ongali, 2010, Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease, Am. J. Pathol., 177, 3071, 10.2353/ajpath.2010.100339 · DOI
  39. Poduslo, 2001, Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease, Neurobiol. Dis., 8, 555, 10.1006/nbdi.2001.0402 · DOI
  40. Qutub, 2005, Glucose transport to the brain: a systems model, Brain Res. Brain Res. Rev., 49, 595, 10.1016/j.brainresrev.2005.03.002 · DOI
  41. Rabie, 2011, Impaired hypoxic response in senescent mouse brain, Int. J. Dev. Neurosci., 29, 655, 10.1016/j.ijdevneu.2011.06.003 · DOI
  42. Rancillac, 2012, Impaired neurovascular coupling in the APPxPS1 mouse model of Alzheimer's disease, Curr. Alzheimer Res., 9, 1221, 10.2174/156720512804142859 · DOI
  43. Richard, 2010, Morphometric changes in the cortical microvascular network in Alzheimer's disease, J. Alzheimers Dis., 22, 811, 10.3233/JAD-2010-100849 · DOI
  44. Sasaki, 2001, Age-related changes of glutathione content, glucose transport and metabolism, and mitochondrial electron transfer function in mouse brain, Nucl. Med. Biol., 28, 25, 10.1016/S0969-8051(00)00180-3 · DOI
  45. Simpson, 1994, Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease, Ann. Neurol., 35, 546, 10.1002/ana.410350507 · DOI · Paper page
  46. Starr, 2009, Blood–brain barrier permeability in Alzheimer's disease: a case-control MRI study, Psychiatry Res., 171, 232, 10.1016/j.pscychresns.2008.04.003 · DOI
  47. Valla, 2008, FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice, Int. J. Dev. Neurosci., 26, 253, 10.1016/j.ijdevneu.2008.02.003 · DOI
  48. Wahlund, 2000, Contrast-enhanced MRI of white matter lesions in patients with blood–brain barrier dysfunction, Ann. N. Y. Acad. Sci., 903, 477, 10.1111/j.1749-6632.2000.tb06402.x · DOI
  49. Zerbi, 2012, Microvascular cerebral blood volume changes in aging APP(swe)/PS1 (dE9) AD mouse model: a voxel-wise approach, Brain Struct. Funct., 218, 1085, 10.1007/s00429-012-0448-8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Do, T. M., Alata, W., Dodacki, A., Traversy, M.-T., Chacun, H., Pradier, L., Scherrmann, J.-M., Farinotti, R., Calon, F., & Bourasset, F.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2014-06
Volume
81
Pages
311-317
ISSN
0028-3908
DOI
10.1016/j.neuropharm.2014.02.010
Cited by
77
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review